Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Pediatr Blood Cancer. 2018 Dec 11;66(4):e27578. doi: 10.1002/pbc.27578

Figure 5:

Figure 5:

Comparison of the cumulative dosages and AUCs of the both the PK-guided and an MTD (2.0 mg/m2) approach, which was simulated from patients with an AUC target of 120–160 ng/ml*h. (Stipled bars represent PK-guided dosing approach and bars with diagonal lines represent MTD dosing approach.)